Federica Carrieri

Federica Carrieri

Auto-generated profile, based on publicly available information

Federica Carrieri

Department of Medicine and Aging Sciences G. d'Annunzio University of Chieti‐Pescara Chieti Italy

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2026 in Diabetic Medicine
Verified
Journal Article
Closed access
FCFederica Carrieri
Federica Carrieri
ESEleanor M. Scott
Eleanor M. Scott
HMHelen R. Murphy
Helen R. Murphy

17 August 2026 in Acta Diabetologica
Verified
Journal Article
Open access
Maria Pompea Antonia BaldassarreMaria Pompea Antonia Baldassarre
Maria Pompea Antonia Baldassarre
FCFederica Carrieri
Federica Carrieri
ASAndrea Sablone
Andrea Sablone
AMANNALISA MAROTTA
ANNALISA MAROTTA
PRPaola Ranalli
Paola Ranalli
GFGLORIA FORMOSO
GLORIA FORMOSO
Aims: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) increase haematocrit and may cause erythrocytosis, creating uncertainty in type 2 diabetes management. Most available data derive from administrative registries or mixed, non-diabetic and/or non-European population. This study aimed to assess the onset, clinical characteristics and management outcomes of people with type 2 diabetes developing SGLT2i-associated erythrocytosis in a routine clinical setting. Methods: This retrospective, single-centre cohort study included adults with type 2 diabetes who developed at least one episode of erythrocytosis (haematocrit ≥ 48% in women, ≥ 49% in men) during the first year after initiation of SGLT2i therapy. Haemoglobin and haematocrit were collected at baseline, at erythrocytosis onset, and at 6 and 12 months with the first erythrocytosis episode defined as the “index date”. No time effect or effect modification across predictive variables was observed. Management included no intervention in 84.1%, SGLT2i discontinuation in 5.3%, and phlebotomy in 4.5%. JAK2 V617F testing was performed in 19 cases, yielding negative results. Results: Erythrocytosis was detected in 3.4% of subjects ( n = 132 out of 3,848). The cohort was predominantly male (87.9%), with a median age of 68.4 years and diabetes duration of 10.5 years. Cardiovascular comorbidities were common. The median time from SGLT2i initiation to erythrocytosis was 11.9 months. Over 12 months, haematocrit and haemoglobin levels remained stable, with no thrombotic events. Conclusions: SGLT2i-associated erythrocytosis is an uncommon, stable, and seemingly low-risk phenomenon. However, it may trigger unnecessary interventions, including treatment discontinuation. These findings highlight a gap between the benign nature of this effect and real-world practice, supporting the need for evidence-based, multidisciplinary guidelines to preserve SGLT2i cardiorenal benefits and optimise patient management.

21 June 2026 in Diabetic Medicine
Verified
Journal Article
Open access
MSMaria‐Eleni Syleouni
Maria‐Eleni Syleouni
TLTara T. M. Lee
Tara T. M. Lee
FCFederica Carrieri
Federica Carrieri
ESEleanor M. Scott
Eleanor M. Scott
AMAesha Khan Mirón
Aesha Khan Mirón
HMHelen R. Murphy
Helen R. Murphy
Aims: The Automated Insulin Delivery among Pregnant women with Type 1 diabetes (AiDAPT) trial demonstrated that using the CamAPS FX automated insulin delivery (AID) was associated with improved glycaemic outcomes. This study aimed to assess the clinical and economic impact of improving third‐trimester HbA1c. Methods: Using the AiDAPT data, a health economics model was built to estimate clinical outcomes and healthcare resource utilisation associated with third‐trimester HbA1c categories (<42 mmol/mol, 42–53 mmol/mol, ≥53 mmol/mol). AiDAPT HbA1c distribution and associated clinical outcomes (obstetric: pre‐eclampsia, delivery method; neonatal: length of stay in normal/critical/intensive care) were used to estimate perinatal complications. UK‐specific healthcare costs were extracted from the NHS National Schedule and other published sources. Total costs to the UK healthcare system were estimated using an incremental 3.3 mmol/mol (0.3%) HbA1c reduction observed with CamAPS FX AID over Standard Care in AIDAPT. Results: In the model, HbA1c improvement with CamAPS FX AID was associated with projected reductions in pre‐eclampsia risk (−13%), high dependency neonatal care days (−16%), neonatal intensive care unit days (−12%) and clinic visits. The model projected cost reduction for the NHS healthcare system of £6,696,636 under conservative modelling assumptions, being cost saving at 96.8% of the simulations. The projected incremental cost difference per woman treated with CamAPS FX AID was ‐£1016, mainly derived from a modelled shift in the distribution of neonatal care, with reduced length of stay in high dependency neonatal intensive care. Conclusion: CamAPS FX AID improves third‐trimester HbA1c with projected cost reductions for the UK healthcare system.

18 March 2025
Verified
Other
Open access
ELEONORA ARUFFOELEONORA ARUFFO
ELEONORA ARUFFO
Alessandra MascitelliAlessandra Mascitelli
Alessandra Mascitelli
PCPiero Chiacchiaretta
Piero Chiacchiaretta
FCFederica Carrieri
Federica Carrieri
MBMaria Pompea Antonia Baldassarre
Maria Pompea Antonia Baldassarre
Piero Di CarloPiero Di Carlo
Piero Di Carlo
Exposure to atmospheric compounds increases the risk of type 2 diabetes. In our study, we will show a derived exposure-response curve from the relative risk to develop type 2 diabetes because of exposure to different pollutants, i.e. particulate matter (PM2.5 and PM10), nitrogen dioxide (NO2), and ozone (O3). The curve is used to estimate a worldwide map of relative risk and the percentage of the attributable burden for each pollutant, using high resolution dataset of atmospheric pollutants from satellite observations. Finally, we will show the validation of the model comparing the modeled percentage of the numbers of patients that are affected by type 2 diabates also because of pollutants exposure with a regional analysis of the attributable patients affected by type 2 diabetes.